Miklya Ildikó
Semmelweis Egyetem, AOK, Farmakológiai és Farmakoterápiás Intézet, Budapest, Hungary.
Neuropsychopharmacol Hung. 2009 Dec;11(4):217-25.
Due primarily to developments in immunology, chemotherapy and hygiene the estimated life expectancy at birth increased during the last century from about 55 years to 80 years. Since the human Technical Life Span (TLSh) is about 120 years and life expectancy is today steadily increasing by about 2.2 months/year, a life span of 100 years may appear quite soon. Knoll developed (-)-deprenyl, the first anti-aging drug, the prophylactic administration of which increased significantly the average life span of animals. (-)-Deprenyl became a world-wide used experimental tool as the first selective inhibitor of B-type MAO and being the unique MAO inhibitor free of the cheese effect was introduced to treat Parkinson's disease, because it could be administered in combination with levodopa without side effects. However, Knoll demonstrated in his later work that (-)-deprenyl has enhancing qualities already in femto-picomolar concentrations, which leave MAO-B activity unchanged, and the activity of the catecholaminergic neurons in the brain stem and this previously unknown 'enhancer effect' is responsible for the peculiar therapeutic benefits caused by (-)-deprenyl. Knoll proposed 25 years ago to slow the aging of the brain, the decay of behavioral performance, prolong life, and prevent or delay the onset of age-related neurodegenerative diseases such as Parkinson's and Alzheimer's via the prophylactic daily administration of 1 mg (-)-deprenyl. At present (-)-deprenyl belongs to the best known anti-aging drugs and a rapidly growing number of people are already trying to slow the aging of their brain by taking (-)-deprenyl as a prophylactic agent. Nevertheless, up to the present, an exact analysis with placebo control of the capacity of (-)-deprenyl to prevent or delay the onset of neurodegenerative diseases is still missing. It is already very much on the map to perform such a study with this world-wide highly esteemed Hungarian drug.
主要由于免疫学、化疗和卫生学的发展,上个世纪出生时的预期寿命从约55岁增至80岁。由于人类的技术寿命(TLSh)约为120岁,且如今预期寿命正以每年约2.2个月的速度稳步增长,100岁的寿命可能很快就会出现。诺尔研发出了第一种抗衰老药物(-)-司来吉兰,预防性服用该药可显著延长动物的平均寿命。(-)-司来吉兰作为第一种B型单胺氧化酶(MAO)选择性抑制剂,成为了一种全球通用的实验工具,并且作为唯一无奶酪效应的MAO抑制剂被用于治疗帕金森病,因为它可与左旋多巴联合使用而无副作用。然而,诺尔在其后期研究中表明,(-)-司来吉兰在飞摩尔至皮摩尔浓度时就已具有增强特性,这不会改变MAO-B的活性,但会影响脑干中儿茶酚胺能神经元的活性,而这种先前未知的“增强效应”正是(-)-司来吉兰产生特殊治疗效果的原因。25年前,诺尔提议通过每日预防性服用1毫克(-)-司来吉兰来减缓大脑衰老、行为能力衰退、延长寿命,并预防或延缓帕金森病和阿尔茨海默病等与年龄相关的神经退行性疾病的发病。目前,(-)-司来吉兰属于最知名的抗衰老药物,越来越多的人已开始尝试通过服用(-)-司来吉兰作为预防药物来减缓大脑衰老。然而,截至目前,仍缺乏一项使用安慰剂对照对(-)-司来吉兰预防或延缓神经退行性疾病发病能力进行的确切分析。开展针对这种在全球备受推崇的匈牙利药物的此类研究已迫在眉睫。